Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jeffrey A. Wickersham, Kelsey B. Loeliger, Ruthanne Marcus, Veena Pillai, Adeeba Kamarulzaman & Frederick L. Altice. (2016) Patterns of substance use and correlates of lifetime and active injection drug use among women in Malaysia. The American Journal of Drug and Alcohol Abuse 42:1, pages 98-110.
Read now
Read now
Sharon Stancliff, Herman Joseph, Chunki Fong, Terry Furst, SandraD. Comer & Perrine Roux. (2012) Opioid Maintenance Treatment as a Harm Reduction Tool for Opioid-Dependent Individuals in New York City: The Need to Expand Access to Buprenorphine/Naloxone in Marginalized Populations. Journal of Addictive Diseases 31:3, pages 278-287.
Read now
Read now
Michael Soyka, Henry R. Kranzler, Wim van den Brink, John Krystal, Hans-Jürgen Möller & Siegfried Kasper. (2011) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. The World Journal of Biological Psychiatry 12:3, pages 160-187.
Read now
Read now
Adam R. Winstock & Toby Lea. (2010) Diversion and Injection of Methadone and Buprenorphine Among Clients in Public Opioid Treatment Clinics in New South Wales, Australia. Substance Use & Misuse 45:1-2, pages 240-252.
Read now
Read now
Kristie Mammen & James Bell. (2009) The clinical efficacy and abuse potential of combination buprenorphine–naloxone in the treatment of opioid dependence. Expert Opinion on Pharmacotherapy 10:15, pages 2537-2544.
Read now
Read now
Articles from other publishers (42)
Yatan Pal Singh Balhara, Priyanka Saha, Merlin Mathew, Mukul Kumar, Arpit Parmar, Rakesh Lal & Siddharth Sarkar. (2023) Nonprescription use of buprenorphine tablets among patients at a tertiary care addictive disorder treatment center in India: Observations and implications. Journal of Opioid Management 19:5, pages 403-411.
Crossref
Crossref
Nikki Bozinoff, Vitor Soares Tardelli, Dafna Sara Rubin-Kahana & Bernard Le Foll. (2022) Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review. Harm Reduction Journal 19:1.
Crossref
Crossref
Salim Mezaache, Patrizia Carrieri, Laélia Briand-Madrid, Virginie Laporte, Alain Morel, Daniela Rojas Castro & Perrine Roux. (2021) Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France. Harm Reduction Journal 18:1.
Crossref
Crossref
Christopher K. Blazes & Jonathan D. Morrow. (2020) Reconsidering the Usefulness of Adding Naloxone to Buprenorphine. Frontiers in Psychiatry 11.
Crossref
Crossref
Marco Riglietta. (2020) Buprenorphine implants: review of literature evidence and impacts on subjects with opioid use disorders. Minerva Psichiatrica 61:1 Suppl. 2.
Crossref
Crossref
Naveen K. Dhagudu, Atul Ambekar, Alok Agrawal, Ravindra Rao, Ashwani K. Mishra, Raka Jain & Shalini Singh. (2020) Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double‐blind, within‐subject, crossover study among opioid‐dependent subjects. Drug and Alcohol Review 39:5, pages 595-603.
Crossref
Crossref
Jia‐shin Chen. (2019) Therapy without a prescription: buprenorphine/naloxone diversion and the therapeutic assemblage in Taiwan. Sociology of Health & Illness 42:3, pages 596-609.
Crossref
Crossref
Theodore J. Cicero, Matthew S. Ellis & Howard D. Chilcoat. (2018) Understanding the use of diverted buprenorphine. Drug and Alcohol Dependence 193, pages 117-123.
Crossref
Crossref
Mohamed Saleem, Helen Martin, Anne Tolya & Penny Coates. (2017) Do all screening immunoassay positive buprenorphine samples need to be confirmed?. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 54:6, pages 707-711.
Crossref
Crossref
Jermaine D. Jones, Jeanne M. Manubay, Shanthi Mogali, Verena E. Metz, Gabriela Madera, Suky Martinez, Mudassir Mumtaz & Sandra D. Comer. (2017) Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. Drug and Alcohol Dependence 179, pages 362-369.
Crossref
Crossref
Preeti Barnwal, Saibal Das, Somnath Mondal, Anand Ramasamy, Tanay Maiti & Arunava Saha. (2016) Probuphine® (buprenorphine implant): a promising candidate in opioid dependence. Therapeutic Advances in Psychopharmacology 7:3, pages 119-134.
Crossref
Crossref
. (2016) Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients. BMC Family Practice 17:1.
Crossref
Crossref
Gabriel J. Culbert, Veena Pillai, Joseph Bick, Haider A. Al-Darraji, Jeffrey A. Wickersham, Martin P. Wegman, Alexander R. Bazazi, Enrico Ferro, Michael Copenhaver, Adeeba Kamarulzaman & Frederick L. Altice. (2016) Confronting the HIV, Tuberculosis, Addiction, and Incarceration Syndemic in Southeast Asia: Lessons Learned from Malaysia. Journal of Neuroimmune Pharmacology 11:3, pages 446-455.
Crossref
Crossref
Sharon L. Walsh, Paul A. Nuzzo, Shanna Babalonis, Victoria Casselton & Michelle R. Lofwall. (2016) Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers. Drug and Alcohol Dependence 162, pages 190-198.
Crossref
Crossref
Essiina Launonen, Hannu Alho, Elina Kotovirta, Isla Wallace & Kaarlo Simojoki. (2015) Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients. International Journal of Drug Policy 26:9, pages 875-882.
Crossref
Crossref
Aishwarya Vijay, Alexander R. Bazazi, Ilias Yee, Adeeba Kamarulzaman & Frederick L. Altice. (2015) Treatment Readiness, Attitudes Toward, and Experiences with Methadone and Buprenorphine Maintenance Therapy Among People Who Inject Drugs in Malaysia. Journal of Substance Abuse Treatment 54, pages 29-36.
Crossref
Crossref
B. Vicknasingam, M.N.M. Dazali, D. Singh, R.S. Schottenfeld & M.C. Chawarski. (2015) Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients. Drug and Alcohol Dependence 152, pages 164-169.
Crossref
Crossref
Donald R TaylorDonald R Taylor. 2015. Managing Patients with Chronic Pain and Opioid Addiction. Managing Patients with Chronic Pain and Opioid Addiction
39
68
.
Camille Cohier, Lucie Chevillard, Patricia Risède, Olivier Roussel & Bruno Mégarbane. (2014) Respiratory effects of buprenorphine/naloxone alone and in combination with diazepam in naive and tolerant rats. Toxicology Letters 228:2, pages 75-84.
Crossref
Crossref
Pertti Heikman, Margareeta Häkkinen, Merja Gergov & Ilkka Ojanperä. (2014) Urine naloxone concentration at different phases of buprenorphine maintenance treatment. Drug Testing and Analysis 6:3, pages 220-225.
Crossref
Crossref
Debasish Basu. (2013)
Commentary on Rosenthal
et al
. (2013): Buprenorphine implant-new hopes, old questions
. Addiction 108:12, pages 2150-2151.
Crossref
Crossref
David Otiashvili, Gvantsa Piralishvili, Zura Sikharulidze, George Kamkamidze, Sabrina Poole & George E. Woody. (2013) Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—Outcomes of a randomized trial. Drug and Alcohol Dependence 133:2, pages 376-382.
Crossref
Crossref
Margareeta Häkkinen, Pertti Heikman & Ilkka Ojanperä. (2013) Parenteral buprenorphine–naloxone abuse is a major cause of fatal buprenorphine-related poisoning. Forensic Science International 232:1-3, pages 11-15.
Crossref
Crossref
Hanna Uosukainen, Hannu Pentikäinen & Ulrich Tacke. (2013) The effect of an electronic medicine dispenser on diversion of buprenorphine-naloxone—experience from a medium-sized Finnish city. Journal of Substance Abuse Treatment 45:1, pages 143-147.
Crossref
Crossref
M.K. Romach, K.A. Schoedel & E.M. Sellers. (2013) Update on tamper-resistant drug formulations. Drug and Alcohol Dependence 130:1-3, pages 13-23.
Crossref
Crossref
B. Rolland, A. Muyssen, T. Danel & O. Cottencin. (2013) Faut-il retirer la buprénorphine haut-dosage du marché français ?. Revue d'Épidémiologie et de Santé Publique 61:2, pages 91-92.
Crossref
Crossref
Hanna Uosukainen, Jussi Kauhanen, Sari Voutilainen, Jaana Föhr, Mika Paasolainen, Jari Tiihonen, Kirsti Laitinen, Ifeoma N. Onyeka & J. Simon Bell. (2013) Twelve-year trend in treatment seeking for buprenorphine abuse in Finland. Drug and Alcohol Dependence 127:1-3, pages 207-214.
Crossref
Crossref
Sharon L. Walsh & Lisa S. Middleton. 2013. Handbook of Methadone Prescribing and Buprenorphine Therapy. Handbook of Methadone Prescribing and Buprenorphine Therapy
163
181
.
Tammi Schaeffer. (2012) Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics. Journal of Medical Toxicology 8:4, pages 400-407.
Crossref
Crossref
Dennis C. Turk, Alec B. O’Connor, Robert H. Dworkin, Amina Chaudhry, Nathaniel P. Katz, Edgar H. Adams, John S. Brownstein, Sandra D. Comer, Richard Dart, Nabarun Dasgupta, Richard A. Denisco, Michael Klein, Deborah B. Leiderman, Robert Lubran, Bob A. Rappaport, James P. Zacny, Harry Ahdieh, Laurie B. Burke, Penney Cowan, Petra Jacobs, Richard Malamut, John Markman, Edward Michna, Pamela Palmer, Sarah Peirce-Sandner, Jennifer S. Potter, Srinivasa N. Raja, Christine Rauschkolb, Carl L. Roland, Lynn R. Webster, Roger D. Weiss & Kerry Wolf. (2012) Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain 153:10, pages 1997-2008.
Crossref
Crossref
Wim van den Brink. 2012. Essential Evidence-Based Psychopharmacology. Essential Evidence-Based Psychopharmacology
235
261
.
Helena Hansen & Mary E. Skinner. (2012) FROM WHITE BULLETS TO BLACK MARKETS AND GREENED MEDICINE: THE NEUROECONOMICS AND NEURORACIAL POLITICS OF OPIOID PHARMACEUTICALS. Annals of Anthropological Practice 36:1, pages 167-182.
Crossref
Crossref
Briony Larance, Louisa Degenhardt, Nick Lintzeris, James Bell, Adam Winstock, Paul Dietze, Richard Mattick, Robert Ali & Danielle Horyniak. (2011) Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug and Alcohol Dependence 118:2-3, pages 265-273.
Crossref
Crossref
Robert N. Jamison, Juliana Serraillier & Edward Michna. (2011) Assessment and Treatment of Abuse Risk in Opioid Prescribing for Chronic Pain. Pain Research and Treatment 2011, pages 1-12.
Crossref
Crossref
Alexander R. Bazazi, Michael Yokell, Jeannia J. Fu, Josiah D. Rich & Nickolas D. Zaller. (2011) Illicit Use of Buprenorphine/Naloxone Among Injecting and Noninjecting Opioid Users. Journal of Addiction Medicine 5:3, pages 175-180.
Crossref
Crossref
Chethan Bachireddy, Alexander R. Bazazi, Ravi Kavasery, Sumathi Govindasamy, Adeeba Kamarulzaman & Frederick L. Altice. (2011) Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: Implications for secondary prevention. Drug and Alcohol Dependence 116:1-3, pages 151-157.
Crossref
Crossref
RICHARD HALLINAN, MARY OSBORN, MILTON COHEN, MALCOLM DOBBIN & ALEX WODAK. (2011) Increasing the benefits and reducing the harms of prescription opioid analgesics. Drug and Alcohol Review 30:3, pages 315-323.
Crossref
Crossref
Danielle Horyniak, Paul Dietze, Briony Larance, Adam Winstock & Louisa Degenhardt. (2011) The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia. International Journal of Drug Policy 22:2, pages 167-171.
Crossref
Crossref
Jennifer P. Schneider, Michele Matthews & Robert N. Jamison. (2010) Abuse-Deterrent and Tamper-Resistant Opioid Formulations. CNS Drugs 24:10, pages 805-810.
Crossref
Crossref
James Bell. (2010) The Global Diversion of Pharmaceutical Drugs. Addiction 105:9, pages 1531-1537.
Crossref
Crossref
Nabarun Dasgupta, Elise J. Bailey, Theodore Cicero, James Inciardi, Mark Parrino, Andrew Rosenblum & Richard C. Dart. (2010) Post-marketing Surveillance of Methadone and Buprenorphine in the United States. Pain Medicine 11:7, pages 1078-1091.
Crossref
Crossref
Jennifer Baker, Petrie M. Rainey, David E. Moody, Gene D. Morse, Qing Ma & Elinore F. McCance‐Katz. (2009) Interactions between Buprenorphine and Antiretrovirals: Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) Didanosine, Lamivudine, and Tenofovir. The American Journal on Addictions 19:1, pages 17-29.
Crossref
Crossref